vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
SCANSOURCE, INC. is the larger business by last-quarter revenue ($766.5M vs $699.9M, roughly 1.1× QuidelOrtho Corp). SCANSOURCE, INC. runs the higher net margin — 2.2% vs -104.7%, a 106.9% gap on every dollar of revenue. On growth, SCANSOURCE, INC. posted the faster year-over-year revenue change (2.5% vs -3.7%). SCANSOURCE, INC. produced more free cash flow last quarter ($28.9M vs $-94.7M). Over the past eight quarters, SCANSOURCE, INC.'s revenue compounded faster (0.9% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
QDEL vs SCSC — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $766.5M |
| Net Profit | $-733.0M | $16.5M |
| Gross Margin | — | 13.4% |
| Operating Margin | -100.7% | 2.3% |
| Net Margin | -104.7% | 2.2% |
| Revenue YoY | -3.7% | 2.5% |
| Net Profit YoY | -3583.4% | -3.3% |
| EPS (diluted) | $-10.78 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $766.5M | ||
| Q3 25 | $699.9M | $739.6M | ||
| Q2 25 | $613.9M | $812.9M | ||
| Q1 25 | $692.8M | $704.8M | ||
| Q4 24 | $707.8M | $747.5M | ||
| Q3 24 | $727.1M | $775.6M | ||
| Q2 24 | $637.0M | $746.1M | ||
| Q1 24 | $711.0M | $752.6M |
| Q4 25 | — | $16.5M | ||
| Q3 25 | $-733.0M | $19.9M | ||
| Q2 25 | $-255.4M | $20.1M | ||
| Q1 25 | $-12.7M | $17.4M | ||
| Q4 24 | $-178.4M | $17.1M | ||
| Q3 24 | $-19.9M | $17.0M | ||
| Q2 24 | $-147.7M | $16.1M | ||
| Q1 24 | $-1.7B | $12.8M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | — | 2.3% | ||
| Q3 25 | -100.7% | 3.5% | ||
| Q2 25 | -29.4% | 3.3% | ||
| Q1 25 | 4.7% | 3.2% | ||
| Q4 24 | -14.2% | 2.5% | ||
| Q3 24 | 2.1% | 2.3% | ||
| Q2 24 | -18.4% | 2.9% | ||
| Q1 24 | -247.3% | 2.3% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | -104.7% | 2.7% | ||
| Q2 25 | -41.6% | 2.5% | ||
| Q1 25 | -1.8% | 2.5% | ||
| Q4 24 | -25.2% | 2.3% | ||
| Q3 24 | -2.7% | 2.2% | ||
| Q2 24 | -23.2% | 2.2% | ||
| Q1 24 | -239.9% | 1.7% |
| Q4 25 | — | $0.75 | ||
| Q3 25 | $-10.78 | $0.89 | ||
| Q2 25 | $-3.77 | $0.87 | ||
| Q1 25 | $-0.19 | $0.74 | ||
| Q4 24 | $-2.54 | $0.70 | ||
| Q3 24 | $-0.30 | $0.69 | ||
| Q2 24 | $-2.20 | $0.66 | ||
| Q1 24 | $-25.50 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $83.5M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | $910.9M |
| Total Assets | $5.7B | $1.7B |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $83.5M | ||
| Q3 25 | $98.1M | $124.9M | ||
| Q2 25 | $151.7M | $126.2M | ||
| Q1 25 | $127.1M | $146.3M | ||
| Q4 24 | $98.3M | $110.5M | ||
| Q3 24 | $143.7M | $145.0M | ||
| Q2 24 | $107.0M | $185.5M | ||
| Q1 24 | $78.5M | $159.1M |
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | — | $910.9M | ||
| Q3 25 | $2.0B | $914.0M | ||
| Q2 25 | $2.8B | $906.4M | ||
| Q1 25 | $3.0B | $901.7M | ||
| Q4 24 | $3.0B | $900.7M | ||
| Q3 24 | $3.2B | $920.9M | ||
| Q2 24 | $3.2B | $924.3M | ||
| Q1 24 | $3.3B | $944.1M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | $5.7B | $1.7B | ||
| Q2 25 | $6.4B | $1.8B | ||
| Q1 25 | $6.5B | $1.7B | ||
| Q4 24 | $6.4B | $1.7B | ||
| Q3 24 | $6.8B | $1.8B | ||
| Q2 24 | $6.7B | $1.8B | ||
| Q1 24 | $6.7B | $1.8B |
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $30.8M |
| Free Cash FlowOCF − Capex | $-94.7M | $28.9M |
| FCF MarginFCF / Revenue | -13.5% | 3.8% |
| Capex IntensityCapex / Revenue | 7.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $30.8M | ||
| Q3 25 | $-45.5M | $23.2M | ||
| Q2 25 | $-46.8M | — | ||
| Q1 25 | $65.6M | $66.1M | ||
| Q4 24 | $63.7M | $-6.2M | ||
| Q3 24 | $117.9M | $44.8M | ||
| Q2 24 | $-97.9M | — | ||
| Q1 24 | $-700.0K | $160.2M |
| Q4 25 | — | $28.9M | ||
| Q3 25 | $-94.7M | $20.8M | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | $64.6M | ||
| Q4 24 | $16.5M | $-8.2M | ||
| Q3 24 | $71.4M | $42.5M | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | $157.7M |
| Q4 25 | — | 3.8% | ||
| Q3 25 | -13.5% | 2.8% | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | 9.2% | ||
| Q4 24 | 2.3% | -1.1% | ||
| Q3 24 | 9.8% | 5.5% | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | 21.0% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | 7.0% | 0.3% | ||
| Q2 25 | 6.1% | 0.3% | ||
| Q1 25 | 8.1% | 0.2% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 6.4% | 0.3% | ||
| Q2 24 | 5.5% | 0.2% | ||
| Q1 24 | 9.3% | 0.3% |
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
